FrancophonIA/ELRC3.0 huggingface dataset:
English: • Primary immunodeficiency syndromes (PID) with impaired antibody production (see section 4.4).
Danish: • Primære immundefekt syndromer (PID) med nedsat antistofproduktion (se pkt.
English: • Multifocal Motor Neuropathy (MMN).
Danish: • Multifokal motorisk neuropati (MMN).
English: The measures taken for the manufacture of KIOVIG are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus and parvovirus B19.
Danish: De forholdsregler, der træffes ved fremstilling af KIOVIG, betragtes som effektive for virus som human immundeficiens-virus (HIV), hepatitis B-virus og hepatitis C-virus samt non-enveloped hepatitis A virus og parvovirus B19.
English: Dilution of KIOVIG with a 5% glucose solution may result in increased blood glucose levels.
Danish: Fortynding af KIOVIG med 5 % glucoseinfusionsvæske kan resultere i øget glucoseniveau i blodet.
English: Precautions for use
Danish: Forholdsregler ved brug
English: Please tell your doctor if you have a kidney disorder.
Danish: • Fortæl venligst din læge, om du har en nyrelidelse.
English: • monitoring of serum creatinine levels
Danish: • monitorering af serum-kreatinin
English: The product should be brought to room or body temperature before use.
Danish: Produktet skal have stuetemperatur eller kropstemperatur før anvendelsen.
English: For obtaining an immunoglobulin solution of 50 mg/ml (5%), KIOVIG 100 mg/ml (10%) should be diluted with an equal volume of the glucose solution.
Danish: For at opnå en immunglobulin opløsning på 50 mg/ml (5 %) bør KIOVIG 100 mg/ml (10 %) fortyndes med samme volumen af glucoseinfusionsvæske.
English: The following dose regimens are given as a guideline.
Danish: Følgende dosering er vejledende.
English: Table 1 Frequency of Adverse Reactions (ADRs) in clinical studies with KIOVIG MedDRA System Organ Class (SOC)
Danish: Tabel 1 Hyppighed af bivirkninger - i kliniske studier med KIOVIG Organklassificering iht.
English: Non-clinical data reveal no special risk for humans based on conventional studies of safety pharmacology and toxicity.
Danish: Ikke-kliniske data baseret på traditionelle undersøgelser af sikkerhedsfarmakologi og toksicitet afslører ingen særlig risiko for mennesker.
English: 1 g/kg over 1-2 consecutive days every 3 weeks.
Danish: 1 g/kg over 1-2 på hinanden følgende dage hver 3. uge.
English: Amnesia, dysarthria, dysgeusia, balance disorder, tremor
Danish: Amnesi, dysartri, dysgeusi, balanceforstyrrelse, tremor
English: Peripheral coldness, phlebitis
Danish: Perifer kulde, flebitis
English: VIAL LABEL (2.5G)
Danish: HÆTTEGLASETIKET (2,5 G)
English: VIAL LABEL (1G)
Danish: HÆTTEGLASETIKET (1 G)
English: OUTER CARTON (1G, 2.5G, 5G, 10G, 20G AND 30G)
Danish: YDERPAKNING (1 G, 2,5 G, 5 G, 10 G, 20 G OG 30 G)
English: The dose interval when steady state has been reached varies from 3-4 weeks.
Danish: Doseringsintervallet varierer fra 3 til 4 uger, når stabil tilstand er nået.
English: Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.
Danish: Patienter, der oplever bivirkninger under behandlingen, bør vente med at føre motorkøretøj og betjene maskiner, indtil bivirkningerne er ophørt.
English: Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected.
Danish: Kliniske erfaringer med immunglobuliner lader antage, at der ikke kan forventes skadelige virkninger på graviditetens forløb eller på fostret og den nyfødte.
English: Solution for infusion (10%) 1 vial
Danish: Infusionsvæske, opløsning (10 %) 1 hætteglas
English: VIAL LABEL (5G, 10G, 20G AND 30G)
Danish: HÆTTEGLAS ETIKET (5 G, 10 G, 20 G OG 30 G)
English: 121 87 to 137 99 75 to 121 104 96 to 114
Danish: 121 87 til 137 99 75 til 121 104 96 til 114
English: • Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4 g/l.
Danish: • Sekundære immundefekter (SID) hos patienter, der lider af alvorlige eller recidiverende infektioner, virkningsløs antimikrobiel behandling samt enten bevist specifikt antistofsvigt (PSAF)* eller serum lgG-niveau på <4 g/l.
English: Maximum immunoglobulin A (IgA) content: 140 micrograms/ml.
Danish: Maksimalt indhold af immunglobulin A (IgA): 140 mikrogram/ml.
English: Headache, high blood pressure, nausea, rash, local reactions (e.g. pain and swelling or other reactions at the infusion site), fever, tiredness.
Danish: Hovedpine, højt blodtryk, kvalme, udslæt, lokale reaktioner (f.eks. smerter og hævelse eller andre reaktioner på infusionsstedet), feber, træthed.
English: MedDRA System Organ Class (SOC)
Danish: MedDRA (SOC)
English: Only clear to slightly opalescent and colourless to pale yellow solutions are to be administered.
Danish: Kun klare til let uigennemsigtige og farveløse til bleggule opløsninger må indgives.
English: Replacement therapy in primary immunodeficiency syndromes
Danish: Substitutionsterapi ved primære immundefekt-syndromer
English: • Very common side effects (may affect more than 1 in 10 people):
Danish: • Meget almindelige bivirkninger (kan ses hos flere end 1 ud af 10 patienter):
English: • Do not use this medicine after the expiry date which is printed on the label and carton after
Danish: • Brug ikke dette lægemidlet efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned.
English: • KIOVIG should be infused intravenously at an initial rate of 0.5 ml/kg bodyweight/hour for 30 minutes.
Danish: • KIOVIG bør infunderes intravenøst med en begyndelseshastighed på 0,5 ml/kg kropsvægt/time i 30 minutter.
English: Do not use if particulate matter or discolouration is observed.
Danish: Må ikke anvendes, hvis der iagttages småpartikler eller misfarvning.
English: 4.44 3.30 to 4.90 4.43 3.78 to 5.16 4.50 3.99 to 4.78
Danish: 4,44 3,30 til 4,90 4,43 3,78 til 5,16 4,50 3,99 til 4,78
English: Local reactions (e.g. infusion site pain/swelling/reaction/pruritus), pyrexia, fatigue
Danish: Lokale reaktioner (f.eks. smerter/hævelse/reaktion/pruritus på injektionsstedet), pyreksi, træthed
English: Other medicines and KIOVIG
Danish: Brug af anden medicin sammen med KIOVIG
English: These include acute renal failure, acute tubular necrosis, proximal tubular nephropathy and osmotic nephrosis.
Danish: Disse omfatter akut nyresvigt, akut tubulær nekrose, proksimal tubulær nefropati og osmotisk nefrose.
English: There is clinical evidence of an association between IVIg administration and thromboembolic events such as myocardial infarction, cerebral vascular accident (including stroke), pulmonary embolism and deep vein thromboses which is assumed to be related to a relative increase in blood viscosity through the high influx of immunoglobulin in at-risk patients.
Danish: Der er kliniske tegn på en forbindelse mellem indgivelse af IVIg og tromboemboliske hændelser som myokardieinfarkt, cerebral vaskulær hændelse (herunder apopleksi), lungeemboli og dybe venetromboser, der antages at skyldes en relativ forøgelse af blodviskositeten på grund af den store indstrømning af immunglobulin hos patienter i risikogruppe.
English: Contusion, pruritus, urticaria, dermatitis, erythema Common Angioedema, acute urticaria, cold sweat, photosensitivity reaction, night sweats, hyperhidrosis
Danish: Kontusion, pruritus, urticaria, dermatitis, erytem Almindelig Angioødem, akut urticaria, koldsved, fotosensitivitetsreaktion, nattesved, hyperhidrose
English: Nervous system disorders Transient ischemic attack, cerebral vascular accident
Danish: Transitorisk iskæmisk attak, cerebral vaskulær hændelse
English: Immunomodulation in adults, and children and adolescents (0-18 years) in:
Danish: Immunmodulation hos voksne samt børn og unge (0-18 år) ved:
English: Adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Danish: Bivirkninger som kuldegysninger, hovedpine, svimmelhed, feber, opkastning, allergiske reaktioner, kvalme, artralgi, lavt blodtryk og moderate lændesmerter kan nu og da forekomme.
English: Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation
Danish: Hypogammaglobulinæmi hos patienter efter allogen hæmatopoietisk stamcelletransplantation
English: Cases of Transfusion Related Acute Lung Injury (TRALI).
Danish: Tilfælde af transfusionsrelateret akut lungeskade (TRALI).
English: Avoidance of concomitant use of loop diuretics.
Danish: Undgå samtidig brug af loopdiuretika.
English: Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4 g/l.
Danish: Sekundære immundefekter (SID) hos patienter, som lider af svære eller tilbagevendende infektioner, ineffektiv antimikrobiel behandling og enten bevist specifikt antistofsvigt (PSAF)* eller med en IgG serumværdi på <4 g/l.
English: Cmax (mg/dl)/(mg/kg) (peak level)
Danish: Cmax (mg/dl)/(mg/dl) (højeste niveau)
English: Blood and lymphatic system disorders
Danish: Blod og lymfesystem Hæmolyse
English: Paediatric patients may be more susceptible to volume overload (see Section 4.9).
Danish: Pædiatriske patienter kan være mere følsomme for hypervolæmi (se pkt.
English: Replacement therapy in secondary immunodeficiency
Danish: Substitutionsterapi ved sekundær immundefekt
English: • After dilution to lower concentrations, immediate use is recommended.
Danish: • Efter fortynding anbefales omgående anvendelse.
English: • Keep the container in the outer carton in order to protect from light.
Danish: • Opbevar beholderen i den ydre karton for at beskytte mod lys.
English: The recommended starting dose is 0.4-0.8 g/kg given once, followed by at least 0.2 g/kg given every three to four weeks.
Danish: Den anbefalede startdosis er 0,4-0,8 g/kg givet én gang efterfulgt af mindst 0,2 g/kg hver tredje til fjerde uge.
English: • 0.4 g/kg given daily for two to five days.
Danish: • 0,4 g/kg dagligt i to til fem dage.
English: When slowing or stopping the infusion may be required
Danish: Når det kan være nødvendigt at sænke hastigheden eller standse infusionen
English: Replacement therapy in adults, and children and adolescents (0-18 years) in:
Danish: Substitutionssterapi hos voksne samt børn og unge (0-18 år) ved:
English: • KIOVIG should be inspected visually for particulate matter and discoloration prior to administration.
Danish: • KIOVIG bør inden indgivelsen nøje undersøges visuelt for småpartikler og misfarvning.
English: For further precautions for use see section 4.4.
Danish: 4.4 for yderligere forholdsregler vedrørende brugen.
English: How to use KIOVIG
Danish: Sådan skal du bruge KIOVIG
English: Human normal immunoglobulin should be infused intravenously at an initial rate of 0.5 ml/kg BW/hr for 30 minutes.
Danish: Humant normalt immunglobulin bør infunderes intravenøst med en begyndelseshastighed på 0,5 ml/kg kropsvægt/time i 30 minutter.
English: Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella.
Danish: Indgivelse af immunglobulin kan i en periode på mindst 6 uger og op til 3 måneder skade effektiviteten af levende svækkede virusvacciner som mæslinger, røde hunde, fåresyge og skoldkopper.
English: Caution should be exercised in prescribing and infusion of IVIg in obese patients and in patients with pre-existing risk factors for thrombotic events (such as a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, hypertension, use of estrogens, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, hypercoagulable disorders, patients with prolonged periods of immobilisation, severely hypovolaemic patients, patients with diseases which increase blood viscosity, patients with indwelling vascular catheters and patients with high dose and rapid infusion).
Danish: Der bør udvises forsigtighed med ordination og infusion af IVIg til adipøse patienter og patienter, der i forvejen har risikofaktorer for trombotiske hændelser som aterosklerose i anamnesen, multiple kardiovaskulære risikofaktorer, fremskreden alder, nedsat kardialt output, forhøjet blodtryk, brug af østrogener, diabetes mellitus og karsygdom eller trombotiske episoder i anamnesen, patienter med erhvervede eller nedarvede trombofile forstyrrelser, tilstande med hyperkoagulation, patienter med længere perioder med immobilisation, stærkt hypovolæmiske patienter samt patienter med sygdomme, der øger blodets viskositet, patienter med anlagte vaskulære katetre og patienter, der får høj dosis og hurtig infusion.
English: Diarrhoea, vomiting, abdominal pain, dyspepsia
Danish: Diarré, opkastning, abdominalsmerter, dyspepsi
English: The in-use stability of KIOVIG after dilution with a 5% glucose solution to a final concentration of 50 mg/ml (5% immunoglobulin) has been demonstrated for 21 days at 2°C to 8°C as well as at 28°C to 30°C; however, these studies did not include the microbial contamination and safety aspects.
Danish: I-brug holdbarheden af KIOVIG efter fortynding med en 5 % glucoseinfusionsvæske til en slutkoncentration på 50 mg/ml (5 % immunglobulin) er blevet påvist til 21 dage ved 2 °C til 8 °C ligesom ved 28 °C til 30 °C, dog omfatter disse undersøgelser ikke den mikrobielle kontaminering og sikkerheds aspekter.
English: Destruction of red blood cells, life-threatening allergic shock, transient stroke, stroke, low blood pressure, heart attack, blood clot in a major vein, blood clot in the main artery of the lung, accumulation of fluid in the lung, positive result of Coombs test, decreased oxygen saturation in blood, transfusion-related acute lung injury.
Danish: Ødelæggelse af røde blodceller, livstruende allergisk shock, forbigående slagtilfælde, slagtilfælde, lavt blodtryk, hjerteanfald, blodprop i en stor vene, blodprop i lungens hovedpulsåre, ophobning af væske i lungerne, positivt resultat af Coombs test, nedsat oxygenmætning i blodet, transfusionsrelateret akut lungeskade.
English: Immunomodulation: Primary immune thrombocytopenia
Danish: Immunmodulation: Primær immune trombocytopeni
English: In patients at risk for thromboembolic adverse reactions, IVIg products should be administered at the minimum rate of infusion and dose practicable.
Danish: Hos patienter i risikogruppe for tromboemboliske reaktioner skal IVIg-produkter indgives med den lavest anvendelige infusionshastighed og dosis.
English: In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped.
Danish: I tilfælde af en uønsket reaktion skal indgivelseshastigheden enten reduceres eller infusionen standses.
English: The in-use stability of KIOVIG after dilution with a 5% glucose solution to a final concentration of 50 mg/ml (5%) immunoglobulin has been demonstrated for 21 days at 2°C to 8°C as well as 28°C to 30°C; however, these studies did not include the microbial contamination and safety aspect.
Danish: I-brug holdbarheden af KIOVIG efter fortynding med en 5 % glucoseinfusionsvæske til en slutkoncentration på 50 mg/ml (5 %) immunglobulin er blevet påvist til 21 dage ved 2 °C til 8 °C ligesom ved 28 °C til 30 °C, disse undersøgelser omfatter imidlertid ikke den mikrobielle kontaminering og sikkerheds aspekt.
English: For safety with respect to transmissible agents, see section 4.4.
Danish: Angående sikkerheden med hensyn til smitsomme stoffer, se pkt.
English: Blood cholesterol increased, blood creatinine increased, blood urea increased, white blood cell count decreased, alanine aminotransferase increased, haematocrit decreased, red blood cell count decreased, respiratory rate increased
Danish: Forhøjet kolesterol i blodet, forhøjet blodkreatinin, urinstof i blodet forhøjet, nedsat antal hvide blodlegemer, forhøjet alaninaminotransferase, nedsat hæmatokrit, nedsat antal røde blodlegemer, øget respirationsfrekvens
English: 0.4 g/kg/d on day 1, possibly repeated once within 3 days for 2-5 days
Danish: 0,4 g/kg/døgn på dag 1, muligvis gentaget en gang i løbet af 3 dage i 2-5 dage
English: • If dilution to lower concentrations is required prior to infusion, KIOVIG may be diluted with 5% glucose solution to a final concentration of 50 mg/ml (5% immunoglobulin).
Danish: • Hvis fortynding til lavere koncentrationer er nødvendig inden infusion, kan KIOVIG fortyndes med 5 % glucoseinfusionsvæske til en slutkoncentration på 50 mg/ml (5 % immunglobulin).
English: The product should be inspected visually for particulate matter and discolouration prior to administration.
Danish: Produktet bør inden indgivelsen undersøges visuelt for småpartikler og misfarvning.
English: • Common side effects (may affect up to 1 in 10 people):
Danish: • Almindelige bivirkninger (kan ses hos op til 1 ud af 10 patienter):
English: In patients at risk for acute renal failure, IVIg products should be administered at the minimum rate of infusion and dose practicable.
Danish: Hos patienter med risiko for akut nyresvigt bør IVIg-produkter indgives ved den mindste infusionshastighed og dosis, der kan gennemføres.
English: 0.2-0.4 g/kg every 3-4 weeks
Danish: 0,2-0,4 g/kg hver 3.-4. uge
English: If dilution prior to infusion is required, KIOVIG may be diluted with 5% glucose solution to a final concentration of 50 mg/ml (5% immunoglobulin).
Danish: Hvis fortynding før infusion er nødvendig, kan KIOVIG fortyndes med 5 % glucoseinfusionsvæske til en slutkoncentration på 50 mg/ml (5 % immunglobulin).
English: The recommended dose is 0.2-0.4 g/kg every three to four weeks.
Danish: Den anbefalede dosis er 0,2-0,4 g/kg hver tredje til fjerde uge.
English: • If dilution is required, 5% glucose solution is recommended.
Danish: • Hvis fortynding er nødvendig, anbefales 5 % glucoseinfusionsvæske.
English: 0.4 g/kg/d for 5 days
Danish: 0,4 g/kg/døgn i 5 dage
English: Certain severe adverse reactions (e.g. headache, flushing, chills, myalgia, wheezing, tachycardia, lower back pain, nausea, and hypotension) may be related to the rate of infusion.
Danish: Visse alvorlige bivirkninger (f.eks. hovedpine, hedeture, kuldegysninger, myalgi, hivende vejrtrækning, takykardi, smerter i lænden, kvalme og hypotension) kan tilskrives infusionshastigheden.
English: • You will be carefully observed during the infusion period with KIOVIG to make sure that you do not suffer a reaction.
Danish: • For at sikre, at du ikke får en reaktion, vil du blive omhyggeligt observeret i den periode, hvor du får infunderet KIOVIG.
English: 0.8-1 g/kg or 0.4 g/kg/d on day 1, possibly repeated once within 3 days for 2-5 days
Danish: 0,8-1 g/kg eller 0,4 g/kg/døgn på dag 1, muligvis gentaget en gang i løbet af 3 dage i 2-5 dage
English: Replacement therapy in primary immunodeficiency starting dose: 0.4-0.8 g/kg maintenance dose: 0.2-0.8 g/kg every 3-4 weeks to obtain IgG trough level of at least 5-6 g/l
Danish: Substitutionsterapi ved primær immundefekt startdosis: 0,4-0,8 g/kg vedligeholdelsesdosis: 0,2-0,8 g/kg hver 3.-4. uge for at opnå IgG-dalkoncentration på mindst 5-6 g/l
English: Chronic sinusitis, fungal infection, infection, kidney infection, sinusitis, upper respiratory tract infection, urinary tract infection, bacterial urinary tract infection, meningitis aseptic
Danish: Kronisk bihulebetændelse, svampeinfektion, infektion, nyreinfektion, bihulebetændelse, infektion i øvre luftveje, infektion i urinvej, bakteriel urinvejsinfektion, aseptisk meningitis
English: Therefore, after receiving immunoglobulins you may have to wait up to 3 months before receiving your live-attenuated vaccine.
Danish: Derfor skal du muligvis vente i op til 3 måneder efter at have fået immunglobuliner, før du får din levende-svækkede vaccine.
English: KIOVIG 100 mg/ml solution for infusion Human Normal Immunoglobulin Intravenous use.
Danish: KIOVIG 100 mg/ml infusionsvæske, opløsning Humant normalt immunglobulin Intravenøs anvendelse.
English: KIOVIG is a solution for infusion in vials of 10, 25, 50, 100, 200 or 300 ml.
Danish: KIOVIG er en infusionsvæske i hætteglas på 10, 25, 50, 100, 200 eller 300 ml Opløsningen er klar eller let uigennemsigtig og farveløs eller bleggul.
English: The dose recommendations are summarised in the following table:
Danish: Følgende tabel indeholder en oversigt over de anbefalede doser:
English: If dilution is required, 5% glucose solution is recommended.
Danish: Hvis fortynding er nødvendig, anbefales 5 % glucoseinfusionsvæske.
English: The recommended infusion rate given under section 4.2 must be closely followed.
Danish: 4.2, skal følges nøje.
English: Pulmonary embolism, pulmonary edema
Danish: Lungeemboli, lungeødem
English: • Any infusion-related adverse events should be treated by lowering the infusion rate or by stopping the infusion.
Danish: • Enhver infusionsrelateret bivirkning bør behandles ved at nedsætte infusionshastigheden eller ved at standse infusionen.
English: • Uncommon side effects (may affect up to 1 in 100 people):
Danish: • Ikke almindelige bivirkninger (kan ses hos op til 1 ud af 100 patienter):
English: Chest tightness, feeling hot, burning sensation, swelling
Danish: Trykken for brystet, varmefølelse, brændende fornemmelse, hævelse
English: Transfusion Related Acute Lung Injury (TRALI)
Danish: Transfusionsrelateret akut lungeskade (TRALI)
English: Table 2 Post-Marketing Adverse Reactions (ARs)
Danish: Tabel 2 Bivirkninger efter markedsføring
English: Special precautions for storage
Danish: Særlige forholdsregler ved opbevaring
English: Solution for infusion The solution is clear or slightly opalescent and colourless or pale yellow.
Danish: Infusionsvæske, opløsning Opløsningen er klar eller let uigennemsigtig og farveløs eller bleggul.
English: • monitoring of urine output
Danish: • monitorering af diuresen
English: Cough, rhinorrhoea, asthma, nasal congestion, oropharyngeal pain, dyspnea
Danish: Hoste, rinoré, astma, nasal kongestion, orofaryngeale smerter, dyspnø
English: Bronchitis, common cold, low red blood cell count, swollen lymph glands, decreased appetite, difficulty in sleeping, anxiety, dizziness, migraine, numbness or tingling of the skin or of a limb, reduced sense of touch, eye inflammation, rapid heartbeat, flushing, cough, runny nose, chronic cough or wheezing (asthma), stuffy nose, sore throat, shortness of breath, diarrhoea, vomiting, abdominal pain, indigestion, contusion, itchingand hives, dermatitis, reddened skin, pain in your back, pain in your joints, pain in your arms or legs, muscle pain, muscle cramps, muscular weakness, chills, accumulation of fluid under the skin, influenza-like illness, pain or discomfort in the chest, lack of strength or feeling of weakness, indisposition, shaking chills.
Danish: Bronkitis, almindelig forkølelse, lavt antal røde blodceller, hævede lymfekirtler, appetitløshed, søvnbesvær, angst, svimmelhed, migræne, følelsesløshed eller snurren i huden, i en arm eller i et ben, nedsat følesans, øjenbetændelse, hurtige hjerteslag (puls), ansigtsrødme, hoste, løbende næse, kronisk hoste eller hvæsen (astma), tilstoppet næse, ondt i halsen, stakåndethed, diarré, opkastning, mavesmerter, fordøjelsesbesvær, blå mærker, kløe og nældefeber, eksem, rødme i huden, smerter i ryggen, ledsmerter, smerter i arme eller ben, muskelsmerter, muskelkramper, muskelsvaghed, kuldegysninger, væskeophobning under huden, influenzalignende sygdom, smerter eller ubehag i brystet, mangel på styrke eller svaghedsfølelse, utilpashed, kulderystelser.